Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group (NASDAQ: APM) announced receipt of a Nasdaq notification dated March 5, 2026, for non-compliance with the $1 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aptorum Group (NASDAQ: APM) announced receipt of a Nasdaq notification dated March 5, 2026, for non-compliance with the $1 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The notification does not affect current trading. Aptorum has a 180-calendar-day cure period until September 1, 2026, to regain compliance and is evaluating options, including a possible reverse stock split, to restore compliance.
Positive
- Nasdaq granted a 180-calendar-day cure period through September 1, 2026
- Notification does not immediately affect listing or trading of APM shares
Negative
- Non-compliance with Nasdaq minimum bid price requirement under Rule 5550(a)(2)
- Company is considering a reverse stock split as a potential remedy
Key Figures
- Nasdaq bid requirement
- $1 per share
- Minimum bid price per Nasdaq Listing Rule 5550(a)(2)
- Grace period
- 180 calendar days
- Period to regain Nasdaq minimum bid compliance to Sept 1, 2026
- Shelf size
- $75,000,000
- Mixed shelf registration on Form F-3 filed Jan 16, 2026
- Shares outstanding
- 6,346,823 shares
- Class A Ordinary Shares as of Jan 14, 2026 (F-3 summary)
- Public float
- $7.55 million
- Public float limiting primary F-3 sales under Instruction I.B.5
- Resale shares
- 54,054 shares
- Class A Ordinary Shares registered for resale via outstanding warrants
- Warrant exercise price
- $0.00
- Exercise price of selling shareholder warrants in F-3 summary
- Post-merger ownership
- 70% / 30%
- Expected split DiamiR holders vs current Aptorum shareholders after merger
Historical Context
-
Collaboration to validate INB’s APOE testing platform in DiamiR’s lab.
-
Two CTAD 2025 Alzheimer’s biomarker abstracts accepted for presentation.
-
Up to $6M registered direct equity financing plus warrants for merger funding.
-
Board and management changes tied to planned DiamiR stock-for-stock merger.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
minimum bid price requirement regulatory
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of
The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.
During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
About Aptorum Group Limited
Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For further information, please contact: investor.relations@aptorumgroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.